LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

38.26 0.84

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

37.64

Max

38.32

Põhinäitajad
By Trading Economics
Sissetulek	638K -65M
Müük	7.5M 7.5M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4.1M -73M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+42.3% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. nov 2025

Turustatistika
By TradingEconomics
Turukapital	-128M 2.6B
Eelmine avamishind	37.42
Eelmine sulgemishind	38.26

Uudiste sentiment

By Acuity

49%

51%

153 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. aug 2025, 16:11 UTC

Suurimad hinnamuutused turgudel

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15. aug 2025, 22:22 UTC

Market Talk

Global Equities Roundup: Market Talk

15. aug 2025, 22:22 UTC

Market Talk

Target Is Falling Behind Its Peers -- Market Talk

15. aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. aug 2025, 20:33 UTC

Market Talk

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15. aug 2025, 20:25 UTC

Tulu

Omandamised, ülevõtmised, äriostud

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15. aug 2025, 20:24 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15. aug 2025, 20:18 UTC

Tulu

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15. aug 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15. aug 2025, 19:12 UTC

Market Talk

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15. aug 2025, 18:32 UTC

Market Talk

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15. aug 2025, 17:33 UTC

Market Talk

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15. aug 2025, 17:23 UTC

Market Talk

Tulu

Deere's Earnings Appear to Be Troughing -- Market Talk

15. aug 2025, 16:27 UTC

Tulu

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15. aug 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. aug 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15. aug 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15. aug 2025, 16:05 UTC

Omandamised, ülevõtmised, äriostud

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15. aug 2025, 15:52 UTC

Omandamised, ülevõtmised, äriostud

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15. aug 2025, 15:36 UTC

Market Talk

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15. aug 2025, 15:29 UTC

Tulu

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15. aug 2025, 15:29 UTC

Omandamised, ülevõtmised, äriostud

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15. aug 2025, 15:28 UTC

Tulu

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15. aug 2025, 15:24 UTC

Market Talk

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15. aug 2025, 15:08 UTC

Market Talk

Applied Materials Is Losing Share in Chips Business -- Market Talk

15. aug 2025, 14:38 UTC

Omandamised, ülevõtmised, äriostud

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15. aug 2025, 14:37 UTC

Omandamised, ülevõtmised, äriostud

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15. aug 2025, 14:37 UTC

Omandamised, ülevõtmised, äriostud

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15. aug 2025, 14:36 UTC

Omandamised, ülevõtmised, äriostud

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15. aug 2025, 14:33 UTC

Omandamised, ülevõtmised, äriostud

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

42.3% tõus

12 kuu keskmine prognoos

Keskmine 54.4 USD 42.3%

Kõrge 65 USD

Madal 47 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

153 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.